This cohort study compares outcomes for patients with hematologic malignant tumors who prophylactically received tixagevimab-cilgavimab against SARS-CoV-2 with those who did not.
Efficacy of Tixagevimab-Cilgavimab as Immunoprophylaxis in Patients With Hematologic Cancer / M. Salvini, P.A. Grossi, A. Cacioppo, M. Merli, G. Pellegrini, M. Brociner, F. Passamonti. - In: JAMA ONCOLOGY. - ISSN 2374-2437. - 10:3(2024), pp. 405-407. [10.1001/jamaoncol.2023.6446]
Efficacy of Tixagevimab-Cilgavimab as Immunoprophylaxis in Patients With Hematologic Cancer
F. PassamontiUltimo
2024
Abstract
This cohort study compares outcomes for patients with hematologic malignant tumors who prophylactically received tixagevimab-cilgavimab against SARS-CoV-2 with those who did not.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
salvini jama.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
469.51 kB
Formato
Adobe PDF
|
469.51 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
